Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Recurrent Clostridium Difficile Infection With RBX7455: A Dose-ranging, Prospective, Single Center, Open Label Phase I Trial

NCT02981316 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02981316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02981316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Recurrent Clostridium Difficile Infection With RBX7455: A Dose-ranging, Prospective, Single Center, Open Label Phase I Trial
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2016
Completion date
July 22, 2020
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium difficile infection